ReviewInternational journal of molecular sciences2020
Autoantibody Biomarkers in Rheumatic Diseases.
Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Daratumumab for autoimmune diseases: a systematic review.RMD open · 2023Pooled it
- Article
- Clinical Associations of Anti-RNPC3 Autoantibodies in Mixed Connective Tissue Disease.ACR open rheumatology · 2026Article
- Risk factors associated with immune-related severe adverse events in patients with cancer: A scoping review.Asia-Pacific journal of oncology nursing · 2025Review
- Next-generation clinically relevant antibody detection: Unlocking electrochemical biosensors for critical disease management.Acta pharmaceutica Sinica. B · 2025Review
- Real World Outcomes of Patients with Aggressive Lymphoma and Autoimmune Disease Treated with CART.Cancers · 2025Article
- A Novel Multiplex Diagnostic Algorithm for Developing an Optimal Patient-Tailored Therapy in Rheumatoid Arthritis Based on Molecular Stratification.International journal of molecular sciences · 2025Article
- Precision Medicine in Rheumatology: The Role of Biomarkers in Diagnosis and Treatment Optimization.Journal of clinical medicine · 2025Review
- CAR-T cell therapy embarks on autoimmune disease.Bone marrow transplantation · 2025Review
- JMJD6 Autoantibodies as a Potential Biomarker for Inflammation-Related Diseases.International journal of molecular sciences · 2024Article
- Pathogenic mechanisms of disease in idiopathic inflammatory myopathies: autoantibodies as clues.Frontiers in immunology · 2024Review
- Anti-SMN autoantibodies in mixed connective tissue disease are associated with a severe systemic sclerosis phenotype.RMD open · 2023Article
- Anti-nuclear autoantibodies in Graves' disease and Graves' orbitopathy.Journal of endocrinological investigation · 2023Article
- Biomarkers in the Pathogenesis, Diagnosis, and Treatment of Systemic Sclerosis.Journal of inflammation research · 2023Review
- A Case of Capillary Leak Syndrome and Intestinal Ischemia Caused by Rheumatoid Vasculitis.Cureus · 2023Article
- Advanced methods and novel biomarkers in autoimmune diseases ‑ a review of the recent years progress in systemic lupus erythematosus.Frontiers in medicine · 2023Review
- Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events.International journal of molecular sciences · 2022Article
- Autoantibodies to Oxidatively Modified Peptide: Potential Clinical Application in Coronary Artery Disease.Diagnostics (Basel, Switzerland) · 2022Article
- Indigenous Nigeria medicinal herbal remedies: A potential source for therapeutic against rheumatoid arthritis.Experimental biology and medicine (Maywood, N.J.) · 2022Review
- Epidemiology of the Epstein-Barr Virus in Autoimmune Inflammatory Rheumatic Diseases in Northern Brazil.Viruses · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoantibodies encountered in patients with systemic rheumatic diseases bear clinical significance as a biomarker to help or predict diagnosis, clinical phenotypes, prognosis, and treatment decision-making. Furthermore, evidence has accumulated regarding the active involvement of disease-specific or disease-associated autoantibodies in the pathogenic process beyond simple association with the disease, and such knowledge has become essential for us to better understand the clinical value of autoantibodies as a biomarker. This review will focus on the current update on the autoantibodies of four rheumatic diseases (rheumatoid arthritis, myositis, systemic sclerosis, and anti-neutrophil cytoplasmic antibody associated vasculitis) where there has been a tremendous progress in our understanding on their biological effects and clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.